Income statement
USD
Annual
| Metric | 2017 | 2016 | 2007 |
|---|---|---|---|
| Revenue | 3M | 3M | 51K |
| Gross Profit | 2M | 1M | -184K |
| Operating Income | 1M | 1M | -184K |
| EBITDA | 1M | 1M | -26K |
| Net Income | 1M | 1M | -382K |
| EPS (Diluted) | — | — | — |
Healthcare
Live Price
Offline$0.0002
+0.00% today
Window Change
+0.00%
Window
May 27, 2026 → Jun 17, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 16 bars · May 27, 2026 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Anbc, Inc. (SYUP) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (May 27, 2026 → Jun 17, 2026). Baseline metrics include revenue growth of +10.0%, EPS growth of -70.9%, a dividend yield of 0.0%. What stands out right now is revenue +10.0%, EPS -70.9%, free cash flow +12035.0% with operating margin 42.8% and ROIC 70.4%. Valuation is more restrained than many high-expectation growth names at P/E 0.0 and price/sales 0.0. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines SYUP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SYUP
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SYUP Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SYUP and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$50.9K
-98.2% YoY
FY Net Income
-$382.2K
-131.6% YoY
Free Cash Flow
-$336.8K
-5285.8% YoY
Revenue Growth
+10.0%
EPS Growth
-70.9%
Gross Margin
49.1%
Net Margin
41.1%
Income statement
USD
| Metric | 2017 | 2016 | 2007 |
|---|---|---|---|
| Revenue | 3M | 3M | 51K |
| Gross Profit | 2M | 1M | -184K |
| Operating Income | 1M | 1M | -184K |
| EBITDA | 1M | 1M | -26K |
| Net Income | 1M | 1M | -382K |
| EPS (Diluted) | — | — | — |
Balance sheet
USD
| Metric | 2017 | 2016 | 2007 |
|---|---|---|---|
| Cash & Equivalents | 79K | 11K | 10K |
| Total Assets | 3M | 2M | 6M |
| Total Liabilities | 809K | 501K | 5M |
| Shareholder Equity | 2M | 1M | 1M |
| Total Debt | 0 | 0 | 4M |
| Net Debt | -79K | -11K | 4M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
79K
+1356.1% YoY
Capital Expenditures
415K
Free Cash Flow
337K
-5285.8% YoY
Key ratios
Gross Margin
49.1%
Operating Margin
42.8%
Net Margin
41.1%
ROE
86.0%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.